Press Releases
-
Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health
Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health
Mar 13, 2022
-
Society of Toxicology Announced ScitoVation’s Senior Research Fellow, Jeffrey W. Fisher, PhD, Awarded 2022 SOT Arnold J. Lehman
ScitoVation has announced that Jeffrey W. Fisher, PhD has been awarded the 2022 Society of Toxicology (SOT) Arnold J. Lehman Award.
Mar 14, 2022
-
Rho Named A 2022 Health Care Leadership Award Winner by Triangle Business Journal
Rho Named A 2022 Health Care Leadership Award Winner by Triangle Business Journal March 15, 2022 - North Carolina-based Triangle Business Journal recently unveiled the winners of its 2022 class of Health Care Leadership Awards, naming Rho as one of this year’s honorees. The global, full-service contract research organization (CRO) was chosen from a pool of Triangle-area nominees that work in a number of health care settings, including major hospital systems, small physician groups, life sciences firms and nonprofit health charities. "The honorees of this year’s Health Care Leadership Awards are making a significant impact on the quality of health care in the Triangle region," said Jason Christie, market president and publisher of TBJ. "This year’s honorees really are heroes in our community. Triangle Business Journal is pleased to honor them.”
Mar 14, 2022
-
Curebase Rapidly Reaches Growth Milestone
Decentralized Clinical Trial Platform Provider Welcomes 100th Teammate
Mar 14, 2022
-
Tesis Biosciences Partners with Frontier Management to Provide Exclusive Pharmacogenetic Testing for Residents of Frontier’s Senior Living Facilities
Tesis Biosciences Partners with Frontier Management to Provide Exclusive Pharmacogenetic Testing for Residents of Frontier’s Senior Living Facilities
Mar 15, 2022
-
Enveda Biosciences Adds Drug Development Leaders to Scale Efforts and Accelerate Progress
-
Calyx EDC Selected for RWE Data Collection in Lengthy, Late Phase Trial
Leading pharmaceutical company trusts Calyx to meet accelerated timelines and support multi-year trials
Feb 20, 2022
-
VitaDAO and Molecule AG partner with Apollo Health Ventures to build the longevity biotech & Web3 ecosystem
Molecule has announced a tripartite partnership with Apollo Health Ventures and VitaDAO.
Feb 20, 2022
-
MicrobioSeq Releases PCR-based Microbial Antibiotic Resistance Gene Analysis Service
MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics MicrobioSeq is committed to delivering comprehensive microbial solutions to human health, agriculture, the environment, and industry by characterizing microbiomes and leveraging microorganisms. The company has recently announced the launch of PCR-based microbial antibiotic resistance gene analysis service to help researchers develop new antimicrobial medicines to address the worldwide threat of antibiotic resistance.
Feb 1, 2022
-
CD Genomics: Bioinformatics-Analysis Division Provides Genotyping Analysis Service for Studying Genetic Variations
-
CD ComputaBio Launches Homology Modeling Service for Drug Screening and Discovery
As a reliable computational biology service provider based in New York, CD ComputaBio has recently launched homology modeling service to help researchers deeply understand the structure-activity relationship of the target protein, and provide strong support for structure-based rational drug design, protein function research, and protein engineering research. Relying on its professional team and advanced technology, as well as high-quality products and services, CD ComputaBio has gained a solid reputation.
Feb 21, 2022
-
CD ComputaBio Releases Molecular Docking Service for Enzymology Research and Drug Design
CD ComputaBio, a reliable computational biology service provider located in New York, always hammers at researches and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. Recently, the product manager announced the launch of molecular docking service, which has a wide range of applications in the field of enzymology research and drug design.
Feb 13, 2022
-
Curebase and CoBTeK (team from Côte d’Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy
Curebase and CoBTeK (team from Côte d’Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy
Feb 21, 2022
-
Sinocompound announces commercial-scale production of QPhos ligand
Sinocompound has today announced production of the phosphine-based QPhos ligand in kilogram quantities for commercial use.
Mar 2, 2022
-
Rho Experts to Present at 5th Annual Gene Therapy for Rare Disorders Conference
Rho, a global full-service contract research organization (CRO), is sharing its drug development success and expertise in gene therapy research during the 5th Annual Gene Therapy for Rare Disorders Conference, taking place in Boston, Massachusetts from March 7-10. Rho’s Associate Director of Regulatory Strategy, Joseph Watson, Senior Director of Nonclinical Development, Brenda Faiola, and Research Scientist Kelsey Behrens will be giving a presentation titled, “Nonclinical Considerations to Enable a Successful Clinical Program.” The March 9 presentation at 2:00 p.m. will discuss key design and execution components, for nonclinical studies, necessary to enable clinical studies. The following items will be addressed: ü Considerations for gene therapy programs regarding animal models, dose selection, and delivery device compatibility ü Lessons Rho has learned in interacting with the FDA across various gene therapy programs ü Gene therapy approval examples that highlight key nonclinical considerations
Feb 22, 2022
-
Creative Biogene: A Premier Partner in the Exploration of Pathogenesis of Mitochondrial-Associated Diseases
Creative Biogene has become the premier partner to cooperate in the exploration of the pathogenesis of mitochondrial-associated diseases.
Feb 23, 2022
-
Pronalyse Launches Antibody Drug Conjugates (ADCs) Characterization Service for Drug Discovery
Pronalyse, a new division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services for over 10 years. Creative Proteomics Pronalyse recently announced the launch of antibody-drug conjugates (ADCs) characterization service to ensure the safety and effectiveness of ADCs drugs.
Feb 14, 2022
-
Lipidomics Bioinformation Analysis Now Available by Creative Proteomics’s Lipidomics Platform
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnological and pharmaceutical companies. The company has recently announced the launch of fully-developed lipidomics bioinformation analysis service to screen differential lipid molecules and analyze their pathways, revealing the physiological mechanism of their changes.
Feb 10, 2022
-
Creative Proteomics Metabolomics Expands Service Offering with the Launch of Microbial Metabolomics Solutions
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. With deep industry and business process expertise and a good reputation in providing contract services specialized for metabolomics, Creative Proteomics Metabolomics announced the launch of microbial metabolomics service to promote a comprehensive understanding of microbial physiology.
Feb 8, 2022
-
ERGOMED announces launch of its Rare Disease Innovation Center™
ERGOMED announces launch of its Rare Disease Innovation Center™ Rare Disease Innovation Center to provide strategic guidance and tailored innovative solutions to sponsors focused on rare disease drug development Raleigh, North Carolina, February 28, 2022 – ERGOMED plc (LSE: ERGO) a leading Clinical Research Organization focused on rare disease drug development today announced the establishment of its Rare Disease Innovation Center.
Feb 27, 2022